← FDA DRUG APPROVALS

FDA ANDA · ANDA208740

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Sponsor: APOTEX

APPLICATION
ANDA208740
TYPE
ANDA
ORIGINAL APPROVAL
2021-06-16
LATEST ACTION
2024-07-11
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATEDiscontinued
EMTRICITABINE 200MG, TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET · ORAL

Approval history

2024-07-11Labeling · Supplement 1 · standardAP
2021-06-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →